# OnCo record clasp-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/clasp-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "clasp-therapeutics" ;
  schema:name "Clasp Therapeutics"@en ;
  schema:description "Clasp Therapeutics makes off-the-shelf T cell engagers that recognise fragments of mutated cancer proteins, such as mutant p53 and KRAS, shown on the surface of tumour cells. Its first medicine, for cancers with a specific p53 mutation, has been in a phase 1 trial since 2025."@en ;
  schema:url <https://onco.cc/companies/clasp-therapeutics/>, <https://www.clasptx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.clasptx.com/>, <https://www.clasptx.com/press-release-publications/clasp-therapeutics-launches-with-150-million-to-pioneer-precision-immuno-oncology-using-next-generation-t-cell-engagers-with-unparalleled-specificity>, <https://www.clasptx.com/press-release-publications/esmo2025>, <https://www.clasptx.com/press-release-publications/clasp-therapeutics-unveils-first-in-class-kras-t-cell-engager-clsp-5282-at-aacr-2026> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/cd3/> ;
  onco:trials <https://onco.cc/trials/nct06778863/> .